An update on methods for detection of prognostic and predictive biomarkers in melanoma

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Gerardo Espinoza¹  Divya Kenchappa¹  Ajay Singh¹  Yvonne M. Saenger¹  Yadriel Bracero¹  Oluwaseyi Adeuyan²  Emily R. Gordon²  Larisa J. Geskin³ 

[1] Albert Einstein College of Medicine, Bronx, NY, United States;Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States;Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States;

关键词: immunotherapy;    checkpoint inhibition;    predictive biomarker;    prognostic biomarker;    melanoma;   

DOI  :  10.3389/fcell.2023.1290696

 received in 2023-09-07, accepted in 2023-10-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

The approval of immunotherapy for stage II-IV melanoma has underscored the need for improved immune-based predictive and prognostic biomarkers. For resectable stage II-III patients, adjuvant immunotherapy has proven clinical benefit, yet many patients experience significant adverse events and may not require therapy. In the metastatic setting, single agent immunotherapy cures many patients but, in some cases, more intensive combination therapies against specific molecular targets are required. Therefore, the establishment of additional biomarkers to determine a patient’s disease outcome (i.e., prognostic) or response to treatment (i.e., predictive) is of utmost importance. Multiple methods ranging from gene expression profiling of bulk tissue, to spatial transcriptomics of single cells and artificial intelligence-based image analysis have been utilized to better characterize the immune microenvironment in melanoma to provide novel predictive and prognostic biomarkers. In this review, we will highlight the different techniques currently under investigation for the detection of prognostic and predictive immune biomarkers in melanoma.

【 授权许可】

Unknown   
Copyright © 2023 Adeuyan, Gordon, Kenchappa, Bracero, Singh, Espinoza, Geskin and Saenger.